Literature DB >> 23460559

Management of malignant insulinoma.

J C Ferrer-García1, V Iranzo González-Cruz, S Navas-DeSolís, M Civera-Andrés, C Morillas-Ariño, A Merchante-Alfaro, C Caballero-Díaz, C Sánchez-Juan, C Camps Herrero.   

Abstract

AIM: Malignant insulinoma is an infrequent functional endocrine tumor of the pancreas. Adequate therapy is a demanding challenge for oncologists and endocrinologists.
OBJECTIVE: To evaluate the results of multidisciplinary management of malignant insulinoma.
MATERIALS AND METHODS: Retrospective review of patients with malignant insulinoma treated from 1995 to 2011.
RESULTS: Seven patients with malignant insulinoma were included: four males and three females; median age was 61.8 years (range 37-78). Six tumors were sporadic and one was diagnosed in a patient with a type 1 multiple endocrine neoplasia (MEN-1). Surgery was performed in six cases and one patient was considered unresectable. Hypoglycemias persisted in all cases and somatostatin analogs, glucocorticoids and diazoxide were used. Two patients received everolimus. Other techniques were chemoembolization and internal radiation therapy with yttrium-90. Successful liver transplant was done in the patient with MEN-1.
CONCLUSION: Hypoglycemia management is complex and requires multiple therapies. Further evaluations will be necessary to determine the best treatment.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23460559     DOI: 10.1007/s12094-012-0996-7

Source DB:  PubMed          Journal:  Clin Transl Oncol        ISSN: 1699-048X            Impact factor:   3.405


  22 in total

1.  Management of intractable hypoglycemia with Yttirum-90 radioembolization in a patient with malignant insulinoma.

Authors:  Prakash Chandra; Shadi Sadeghi Yarandi; Natasha Khazai; Sol Jacobs; Guillermo E Umpierrez
Journal:  Am J Med Sci       Date:  2010-11       Impact factor: 2.378

2.  Glycemic control in patients with insulinoma treated with everolimus.

Authors:  Matthew H Kulke; Emily K Bergsland; James C Yao
Journal:  N Engl J Med       Date:  2009-01-08       Impact factor: 91.245

3.  Transient efficacy of octreotide and pasireotide (SOM230) treatment in GIP-dependent Cushing's syndrome.

Authors:  V Preumont; L M Mermejo; P Damoiseaux; A Lacroix; D Maiter
Journal:  Horm Metab Res       Date:  2011-01-24       Impact factor: 2.936

4.  Treatment with somatostatin analogs and chemoembolization of liver metastases for severe hypoglycemia in malignant insulinomas.

Authors:  J C Maiza; D Vezzosi; S Grunenwald; P Otal; R Guimbaud; A Bennet; P Caron
Journal:  J Endocrinol Invest       Date:  2011-05-27       Impact factor: 4.256

5.  Somatostatin receptor subtype 5 (SSTR5) mRNA expression is related to histopathological features of cell proliferation in insulinomas.

Authors:  Sandra Valéria de Sá; Maria Lúcia Corrêa-Giannella; Márcio Carlos Machado; Jean Jorge S de Souza; Maria Adelaide Albergaria Pereira; Rosely Antunes Patzina; Sheila Aparecida Coelho Siqueira; Marcel Cerqueira César Machado; Daniel Giannella-Neto
Journal:  Endocr Relat Cancer       Date:  2006-03       Impact factor: 5.678

6.  Pasireotide (SOM230) demonstrates efficacy and safety in patients with acromegaly: a randomized, multicenter, phase II trial.

Authors:  S Petersenn; J Schopohl; A Barkan; P Mohideen; A Colao; R Abs; A Buchelt; Y-Y Ho; K Hu; A J Farrall; S Melmed; B M K Biller
Journal:  J Clin Endocrinol Metab       Date:  2010-04-21       Impact factor: 5.958

7.  Therapies for the medical management of persistent hypoglycaemia in two cases of inoperable malignant insulinoma.

Authors:  Gregory S Y Ong; David E Henley; David Hurley; J Harvey Turner; Phillip G Claringbold; P Gerry Fegan
Journal:  Eur J Endocrinol       Date:  2010-02-17       Impact factor: 6.664

Review 8.  Pancreatic neuroendocrine tumours.

Authors:  N Alexakis; J P Neoptolemos
Journal:  Best Pract Res Clin Gastroenterol       Date:  2008       Impact factor: 3.043

9.  Somatostatin receptors 2 and 5 are the major somatostatin receptors in insulinomas: an in vivo and in vitro study.

Authors:  J Bertherat; F Tenenbaum; K Perlemoine; C Videau; J L Alberini; B Richard; B Dousset; X Bertagna; J Epelbaum
Journal:  J Clin Endocrinol Metab       Date:  2003-11       Impact factor: 5.958

10.  Efficacy of RAD001 (everolimus) and octreotide LAR in advanced low- to intermediate-grade neuroendocrine tumors: results of a phase II study.

Authors:  James C Yao; Alexandria T Phan; David Z Chang; Robert A Wolff; Kenneth Hess; Sanjay Gupta; Carmen Jacobs; Jeannette E Mares; Andrea N Landgraf; Asif Rashid; Funda Meric-Bernstam
Journal:  J Clin Oncol       Date:  2008-09-10       Impact factor: 44.544

View more
  9 in total

Review 1.  Everolimus as first line therapy for pancreatic neuroendocrine tumours: current knowledge and future perspectives.

Authors:  Marco Gallo; Pasqualino Malandrino; Giuseppe Fanciulli; Francesca Rota; Antongiulio Faggiano; Annamaria Colao
Journal:  J Cancer Res Clin Oncol       Date:  2017-04-12       Impact factor: 4.553

2.  ENETS Consensus Guidelines Update for the Management of Patients with Functional Pancreatic Neuroendocrine Tumors and Non-Functional Pancreatic Neuroendocrine Tumors.

Authors:  M Falconi; B Eriksson; G Kaltsas; D K Bartsch; J Capdevila; M Caplin; B Kos-Kudla; D Kwekkeboom; G Rindi; G Klöppel; N Reed; R Kianmanesh; R T Jensen
Journal:  Neuroendocrinology       Date:  2016-01-05       Impact factor: 4.914

Review 3.  Single-cell approaches for molecular classification of endocrine tumors.

Authors:  James Koh; Nancy L Allbritton; Julie A Sosa
Journal:  Curr Opin Oncol       Date:  2016-01       Impact factor: 3.645

Review 4.  Pancreatic insulinomas: Laparoscopic management.

Authors:  Pantelis T Antonakis; Hutan Ashrafian; Alberto Martinez-Isla
Journal:  World J Gastrointest Endosc       Date:  2015-11-10

Review 5.  Carcinoid Syndrome and Hyperinsulinemic Hypoglycemia Associated with Neuroendocrine Neoplasms: A Critical Review on Clinical and Pharmacological Management.

Authors:  Francesca Spada; Roberta E Rossi; Elda Kara; Alice Laffi; Sara Massironi; Manila Rubino; Franco Grimaldi; Sherrie Bhoori; Nicola Fazio
Journal:  Pharmaceuticals (Basel)       Date:  2021-06-04

6.  Diagnostic Difficulties in a Pediatric Insulinoma: A Case Report.

Authors:  Ingrith Miron; Smaranda Diaconescu; Gabriel Aprodu; Ileana Ioniuc; Mihai Radu Diaconescu; Lucian Miron
Journal:  Medicine (Baltimore)       Date:  2016-03       Impact factor: 1.889

7.  Giant insulinoma: report of a case and review of published reports.

Authors:  Kazumitsu Ueda; Tetsuro Taira; Hiroyuki Hakoda; Shoko Nakata; Shinya Okata; Takeshi Nagai; Shigeo Aoki; Hideyuki Mishima; Akihiko Sako; Tsunehiko Maruyama; Minoru Okumura
Journal:  Surg Case Rep       Date:  2016-11-19

8.  Modified linear regression predicts drug-target interactions accurately.

Authors:  Krisztian Buza; Ladislav Peška; Júlia Koller
Journal:  PLoS One       Date:  2020-04-06       Impact factor: 3.240

Review 9.  Surgical Management of Neuroendocrine Tumours of the Pancreas.

Authors:  Regis Souche; Christian Hobeika; Elisabeth Hain; Sebastien Gaujoux
Journal:  J Clin Med       Date:  2020-09-16       Impact factor: 4.241

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.